SCHEDULE: Blue Owl Capital Holdings LP Discloses Stake in Context Therapeutics

Blue Owl Capital Holdings LP has filed a Schedule 13G, reporting beneficial ownership of 5,089,015 shares, representing 5.54% of Context Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• Blue Owl Capital Holdings LP has filed a Schedule 13G, indicating it beneficially owns 5,089,015 shares of Context Therapeutics Inc. common stock.
• This ownership stake represents 5.54% of the class of securities.
• The filing is an amendment (Amendment No. 2) to a previous filing, with the event date requiring this statement being March 31, 2026.
• The percentage is calculated based on 91,879,177 shares of Common Stock outstanding as of May 4, 2026, as reported in Context Therapeutics Inc.'s 10-Q filed on May 6, 2026.
• Blue Owl Capital Holdings LP is organized in Delaware and its principal business office is located at 399 Park Avenue, New York, New York 10022.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an investment firm and does not contain operational or financial performance updates for the company itself.

Positives

• Blue Owl Capital Holdings LP, a significant investment entity, has disclosed a substantial beneficial ownership stake in Context Therapeutics Inc.
• The disclosure indicates a 5.54% ownership, suggesting confidence or strategic interest from a notable investor.
• The reporting is current as of March 31, 2026, providing up-to-date information on significant shareholding.

Risks

• The filing does not explicitly mention any risks or challenges faced by Context Therapeutics Inc. or Blue Owl Capital Holdings LP.
• Potential risks associated with holding a significant stake in a publicly traded company, such as market volatility and regulatory changes, are not detailed.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Context Therapeutics Inc. or Blue Owl Capital Holdings LP regarding future performance or strategy.

Management Comments

• "The reported percentage is calculated based on 91,879,177 shares of Common Stock outstanding as of May 4, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission on May 6, 2026."
• "Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by Blue Owl Capital Holdings LP indicates a significant institutional investor's passive stake in Context Therapeutics Inc., a biotechnology company. Such filings are common as investment firms build positions in companies within the life sciences sector, often driven by the potential for drug development and market approval.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Blue Owl Capital Holdings LP may be viewed positively by other shareholders, indicating institutional interest and potential validation of the company's prospects. However, it does not provide direct operational updates.
• Management: The filing confirms a passive investment by Blue Owl, which typically does not imply direct involvement in management decisions unless the stake crosses certain thresholds or specific agreements are in place.
• Creditors: No direct impact on creditors is indicated by this filing, as it pertains to equity ownership.

Key Dates

Keywords

Schedule 13G, Blue Owl Capital Holdings LP, Context Therapeutics Inc., Beneficial Ownership, SEC Filing, Common Stock, Investment, Securities, Shareholder